Description
A compilation of five sessions as presented during the 2019 HRS Scientific Sessions provides a look at AF Management and Treatment options. The five sessions include:
S-043 Anticoagulation in Challenging Clinical Settings -
Patients with comorbidities like renal disease, CAD or after cryptogenic stroke as well as patients in special situations like e.g. ablation are difficult to manage in terms of stroke prevention. Come and find out how renowned experts in the field try to solve unsolvable clinical settings.
S-051 The Future Roadmap of AF Management - Where Are We Heading in 2019? -
The management of AF is a complex process requiring a comprehensive, multidisciplinary team approach. This session will cover the significant 'pillars' of AF management (i.e. rate/rhythm control, stroke prevention, cardiovascular risk factor management) and demonstrates the role of a patient-centered Integrated Care Management strategy.
S-069 Stroke Prevention in AF: 2019 Therapy Update Core Curriculum -
This session will provide an overview of the current pharmacologic and non-pharmacologic options for stroke prevention in patients with AF. It will include updates on prescribing recommendations, drug interactions and reversal agents for anticoagulants. It will review LAA ligation and occlusion procedures - patient selection and follow up care. It will also cover the periprocedural management of patients on oral anticoagulants.
S-083 Device-Detected Subclinical AF of <24 Hour Duration: To Treat or Not to Treat? -
In this session, world-experts will debate the use of oral anticoagulant therapy to treat pacemaker and ICD patients with subclinical atrial fibrillation.
S-AF03 AF Summit - Approaches to Management of AF -
The AF Summit is a highlighted program that will provide a comprehensive update on discoveries and advancements in AF management. The session will cover evolutions in AF management that are taking place in 2019 based upon the science that has accumulated over the past year. This session will include lectures by leading experts in novel aspects of AF management as well as debates on contemporary controversies impacting clinical practice.
Faculty List
Mintu Turakia, MD, MS, FHRS
Associate Professor
Stanford University, Palo Alto
Peter Kowey, MBBS, PhD, FHRS
Emeritus Chief, Cardiovascular
Lankenau Medical Center
J. C. Hsu, MD
Associate Clinical Professor
University of California, San Diego
D. Steven, MD
Konstatinos Siontis, MD
Mayo Clinic, Rochester
H. Kamel, MD
Andreas Goette, MD
Professor
St. Vincenz Hospitaal Paderborn
Celine Gallagher, BSN, MS
Postdoctoral Fellow/Clinical Nurse
Centre for Heart Rhythm Disorders
Ohad Zive, MD
Director, Cardiac Electrophysiology
MetroHealth Campus Case Western Reserve
H. Hidbuchel, MD
Professor
Antwerp University
J. M. Hendriks, MD
M. L. Callans, MD
K. B. Campbell, MD
D. Atkins, MD
D. C. Shah, MD
I. C. Van Gelder, MD
Univeristy Medical Center Groningen
D. H. Lau, MD
R. S. Passman, MD
Professor of Medicine
Northwestern University
T. V. Glotzer, MD
Professor
Electrophysiology Associates
CME Statements
Accreditation Statement
The Heart Rhythm Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians AMA Designation Statement
The Heart Rhythm Society designates this internet enduring activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Policy
CME Disclosure Policy
The Heart Rhythm Society is committed to the provision of Continuing Medical Education (CME) that is balanced, objective, and evidence-based. The Heart Rhythm Society adheres to the Standards for Commercial Support (SCS) of the Accreditation Council for Continuing Medical Education (ACCME) which requires that those individuals in a position to control the content of an educational activity (including planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all relevant* financial relationships (for self and for individual's spouse/partner) with an ACCME-defined commercial interest** from the preceding 12 months.
Any individual who refuses to disclose financial relationships is disqualified from participating in HRS educational activities. Employees and Owners of ACCME-defined commercial interests may have no role in the planning or implementation of CME activities without a special exception from the HRS Chief Learning Officer that is granted only in specific circumstances that meet stringent ACCME requirements.
ACCME Definitions:
*Relevant financial relationships are financial relationships in any amount, which occurred in the twelve-month period preceding the time that the individual was asked to assume a role controlling content of the CME activity, and which relate to the content of the educational activity, causing a conflict of interest. The ACCME considers financial relationships to create conflicts of interest in CME when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest.
**A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests - unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
Chair Disclosures:
Mintu Turakia, MD, MS, FHRS: Research (Contracted Grants for PIs and Named Investigators only) - Apple Inc.; Janssen Pharmaceuticals; Bristol-Myers Squibb. Honoraria/Speaking/Consulting Fee - Medtronic, Inc.; Biotronik; Abbott Vascular; AliveCor.
Peter Kowey, MBBS, PhD, FHRS: Honoraria/Speaking/Consulting Fee - Daiichi; Acesion Pharma; Bristol-Myers Squibb; Pfizer, Inc.; Johnson and Johnson. Stock or Stock Options - Non-Public (Including Start-up) - CardioNet, Inc..
Speaker Disclosures:
J. C. Hsu, MD: Research (Contracted Grants for PIs and Named Investigators only): Biosense Webster, Biotronik. Honoraria/Speaking/Consulting Fee: Abbott, Medtronic, Boston Scientific, Biotronik, Janssen Pharma
D. Steven, MD: Nothing Relevant to Disclose
Konstatinos Siontis, MD: Nothing Relevant to Disclose
H. Kamel, MD: Honoraria/Speaking/Consulting Fee: Medtronic. Research (Contracted Grants for PIs and Named Investigators only): Briston-Myers Squibb, Roche, Roviant Sciecnes
Andreas Goette, MD: Honoraria/Speaking/Consulting Fee: Berlin Chemie, Medtronic, Boston Scientific, AstraZeneca, Omeicos, Bayer/Schering Pharma. Speakers Bureau: Boehringer Ingelheim
Celine Gallagher, BSN, MS: Nothing Relevant to Disclose
Ohad Zive, MD: Research (Contracted Grants for PIs and Named Investigators only): Biosense Webster
H. Hidbuchel, MD: Nothing Relevant to Disclose
J. M. Hendriks, MD: Honoraria/Speaking/Consulting Fee: Medtronic, Pfizer
M. L. Callans, MD: Honoraria/Speaking/Consulting Fee: Medtronic
K. B. Campbell: MD: Nothing Relevant to Disclose
D. Atkins, MD: Nothing Relevant to Disclose
D. C. Shah, MD: Honoraria/Speaking/Consulting Fee:Biosense Webster, Biosense, Abbott. Research (Contracted Grants for PIs and Named Investigators only): Biosense Webster
I. C. Van Gelder, MD: Nothing Relevant to Disclose
D. H. Lau, MD: Honoraria/Speaking/Consulting Fee: Biotronik, Bayer/Schering Pharma, Boeringer Ingelheim, Abbott.
R. S. Passman, MD: Honoraria/Speaking/Consulting Fee: Janssen Pharma, Medtronic
T. V. Glotzer, MD: Nothing Relevant to Disclose
Content Reviewer:
Peter Aziz, MD, FHRS: Nothing to Disclose.
Content Validation Policy
The Heart Rhythm Society is committed to the provision of Continuing Medical Education (CME) that is balanced, objective, and evidence-based. The Heart Rhythm Society adheres to the Standards for Commercial Support (SCS) of the Accreditation Council for Continuing Medical Education (ACCME) which requires that those individuals in a position to control the content of an educational activity (including planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all relevant financial relationships with an ACCME-defined commercial interest within the 12 months prior to the disclosure.
The Heart Rhythm Society takes steps to assure its learners and the public that the content of certified activities is accurate and reliable. The following principles are applied to the process of validating CME content. The content is peer-reviewed to ensure the following:
Fair Balance - that content is balanced among various options available for treatment and not biased toward a particular product or manufacturer.
Patient Treatment Recommendations - that patient treatment recommendations contained in the content are evidence-based, are appropriate for the target audience, and that the patient treatment recommendations contribute to overall improvement in patient care.
Scientific Validity - that scientific studies cited in the activity conform to standards accepted by the scientific community.
Learning Objectives - that the educational content supports the learning objectives of the activity, and that the objectives stated for performance-in-practice are actionable and measurable.
Omissions - that no seminal studies, data, or best evidence are missing
Contact Information
CME and CoP Certificates will be awarded and available to download and print following the completion of the course and the course evaluation. Should you have any questions regarding your CME certificate, please contact CME@HRSonline.org.